DGAP-News: XPhyto Therapeutics Corp. / Key word(s): Miscellaneous 
XPhyto Therapeutics Corp.: XPhyto European CE-IVD Application for 25-Minute COVID-19 RT-PCR Test 
2021-02-16 / 09:05 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
XPhyto European CE-IVD Application for 25-Minute COVID-19 RT-PCR Test 
VANCOUVER, BC / ACCESSWIRE / February 16, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)( OTCQB:XPHYF)(FSE:4XT) ("XPhyto" 
or the "Company"), and its exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"), are pleased to 
announce that all actions and procedures required for its European regulatory application for the rapid point-of-care 
SARS-CoV-2 (COVID-19) RT-PCR Test System ("Covid-ID Lab") have been completed. 3a expects ISO 13485 approval as a 
medical device manufacturer by late February and European regulatory approval as a commercial in vitro diagnostic 
device (CE-IVD) for Covid-ID Lab by early March. 
Covid-ID Lab was designed to be a rapid, accurate and robust test system with reduced operating costs and increased 
convenience and portability. Initial manufacturing is planned for Germany with additional capacity in other 
jurisdictions to follow. The sales launch in Europe is targeted for April 2021. XPhyto is currently in discussions with 
potential distribution and wholesale partners in Europe and the Middle East. The Company will provide further 
information and updates in due course. 
"We are very pleased with the team's swift development progress," said Hugh Rogers, CEO & Director of XPhyto. "Our goal 
was to create the fastest and most portable COVID-19 PCR test on the market. We are confident in our prospects for an 
expedited approval and look forward to commercial launch in short order." 
XPhyto and 3a are also developing a portfolio of oral biosensor screening tests for detection of bacterial and viral 
infectious diseases, including influenza A, group A strep, stomatitis, periimplantitis, and periodontitis. Additional 
pandemic-focused biosensors are in development, specifically for H1N1 (swine flu), and H5N1 (avian flu). The Company is 
planning commercial launch of its first biosensor product in the second half of 2021. 
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain 
the COVID-19 pandemic. 
About XPhyto Therapeutics Corp. 
XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new 
active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug 
formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging 
active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The 
Company has research and development operations in North America and Europe, with an operational focus in Germany, and 
is currently focused on regulatory approval and commercialization of medical products for European markets. 
XPhyto Therapeutics Corp.: 
Hugh Rogers, CEO and Director 
Investor Inquiries: 
Mr. Knox Henderson 
T: 604-551-2360 
E: info@xphyto.com 
Media Inquiries: 
MC Services AG 
Julia Hofmann, Andreas Jungfer 
T: +49 89 210 228 0 
E: xphyto@mc-services.eu 
Forward-Looking statements 
This news release includes statements containing forward-looking information within the meaning of applicable Canadian 
securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as 
"develop", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "potential", 
"propose" and other similar words, or statements that certain events or conditions "may" or "will" occur, and in this 
release include the statement regarding the Company's goal of building a successful diagnostic, drug delivery, and 
medical cannabis company. Forward-looking statements are only predictions based on the opinions and estimates of 
management at the date the statements are made and are subject to a variety of risks and uncertainties and other 
factors that could cause actual events or results to differ materially from those projected in the forward-looking 
statements, including: that the Company may not succeed in developing a commercial product; that the sale of products 
may not be a viable business; that the Company may be unable to scale its business; product liability risks; product 
regulatory risk; general economic conditions; adverse industry events; future legislative and regulatory developments; 
inability to access sufficient capital from internal and external sources, and/or inability to access sufficient 
capital on favourable terms; currency risks; competition; international risks; and other risks beyond the Company's 
control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise 
any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly 
required by applicable law. 
Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility 
for the adequacy or accuracy of this news release. 
SOURCE: XPhyto Therapeutics Corp. 
=---------------------------------------------------------------------------------------------------------------------- 
2021-02-16 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=----------------------------------------------------------------------------------------------------------------------

1168503 2021-02-16

(END) Dow Jones Newswires

February 16, 2021 03:06 ET (08:06 GMT)